FDA Commissioner Defends Notices to Shah Rukh Khan, Ajay Devgn
- FDA issued surrogate advertising notices to Shah Rukh Khan, Ajay Devgn, and Tiger Shroff.
- Actors have not yet responded to the regulatory notices as of August 2026.
- FDA Commissioner Tukaram Mundhe stated endorsers carry direct responsibility.
- Mundhe denied claims that the regulatory action is a targeted publicity stunt.
- Consumer protection laws hold celebrities accountable for misleading promotions.
Maharashtra Food and Drug Administration Commissioner Tukaram Mundhe pushed back against mounting industry criticism on Wednesday, August 26, 2026, defending the recent regulatory notices sent to top-tier Bollywood actors Shah Rukh Khan, Ajay Devgn, and Tiger Shroff.
Regulatory officials confirmed that the three prominent film stars have yet to submit formal responses regarding their involvement in high-profile surrogate advertising campaigns.
The enforcement action has triggered widespread debate across the Indian entertainment industry and corporate boardrooms alike.
- Officials issued formal notices citing violations related to the promotion of restricted substances through brand extensions.
- Investigators noted that endorsers failed to provide compliance documentation within the stipulated legal timeframe.
- Consumer welfare advocates pointed out that top celebrities command massive influence over impressionable demographics.
Mundhe rejected allegations that the regulatory body targeted the actors for cheap publicity or sensationalism.
"Whatever you promote has to be truthful and compliant with the law," Mundhe told reporters during a media briefing in Mumbai.
"It is the direct responsibility of the endorser to verify what they are putting their face and reputation behind."
Legal analysts observed that this uncompromising stance marks a significant shift in how Indian regulatory agencies handle celebrity accountability in commercial endorsements.
The Anatomy of Surrogate Advertising in Indian Commercial Cinema
Surrogate advertising has long served as a lucrative financial lifeline for Bollywood's biggest stars, who command tens of crores of rupees for commercial endorsements.
When direct promotion of tobacco and alcohol products face strict legislative bans under Indian law, corporations pivot toward clever marketing workarounds.
Companies market mouth fresheners, packaged drinking water, or music CDs bearing identical brand names, fonts, and color palettes as prohibited items.
Consumers instantly connect the substitute product to the core restricted brand, maintaining high market recall without breaking the letter of older statutory frameworks.
Industry reports indicate that surrogate tobacco and pan masala campaigns account for roughly 18% of total celebrity endorsement revenue in the Hindi film industry.
However, government regulators have intensified their scrutiny of these grey-area marketing tactics over the past twenty-four months.
Consumer protection watchdogs argue that using beloved cinematic icons to market products linked to severe public health risks constitutes a deceptive trade practice.
"The lines between the permissible product and the prohibited product are deliberately blurred to deceive the public," public health researchers noted in recent policy papers.
Government figures show that public health expenditures related to tobacco consumption exceed ₹1.5 lakh crore annually, adding immense economic urgency to regulatory crackdowns.
Legal Frameworks and the Rising Accountability of Celebrity Endorsers
The legal landscape governing celebrity endorsements transformed dramatically with the enactment of the Consumer Protection Act of 2019.
Under these provisions, the Central Consumer Protection Authority holds the power to penalize endorsers up to ₹10 lakh for misleading advertisements, with penalties climbing to ₹50 lakh for repeat offenses.
Legal experts emphasized that celebrities can no longer hide behind standard contractual indemnity clauses signed with advertising agencies or corporate brand owners.
- The Consumer Protection Act explicitly makes endorsers liable for deceptive claims and hidden surrogate messaging.
- Regulatory filings reveal that prior warning letters sent to advertising agencies resulted in a compliance rate of less than 35%.
- Statutory guidelines mandate that endorsers conduct due diligence before signing commercial contracts.
Shah Rukh Khan, Ajay Devgn, and Tiger Shroff now find themselves at the center of this stringent legal evolution.
Corporate law specialists pointed out that the failure to respond promptly to the FDA notices could invite stiffer administrative penalties and potential court summons.
"Endorsers have a fiduciary duty to the consumers who trust them," corporate litigators stated in advisory notes circulated this week.
The ongoing standoff sets a high-stakes precedent for future celebrity commercial partnerships across India.
Public Health Crusaders and the Maharashtra FDA Crackdown
Tukaram Mundhe has earned a formidable reputation as a bureaucrat who refuses to bow to political or commercial pressure throughout his decades-long civil service career.
His administration within the Maharashtra FDA prioritizes rigorous enforcement of public health mandates over accommodating powerful corporate lobbies.
Public health organizations have lauded the agency's uncompromising approach, noting that tobacco-related illnesses claim over 13 lakh lives annually across India.
Medical professionals argue that when a megastar like Shah Rukh Khan or Ajay Devgn promotes a pan masala brand, youth perception of the product's danger drops significantly.
"Celebrity endorsement acts as a social license for harmful habits," epidemiologists stated in recent health bulletins.
The state FDA's current initiative aims to dismantle the illusion that A-list actors are immune to regulatory oversight.
Industry insiders revealed that several other production houses and talent management agencies are currently reviewing their active endorsement portfolios in light of the crackdown.
Official data indicates that compliance inquiries have risen by 42% across Maharashtra since the beginning of the fiscal year.
The state agency maintains that the notices serve as an educational and corrective measure designed to enforce absolute transparency in public advertising.
What Next for Bollywood's A-List Brands and Commercial Future
The unfolding regulatory showdown forces Bollywood's elite to re-evaluate their lucrative brand endorsement portfolios.
As major consumer brands shift their marketing budgets toward digital-first campaigns, stars face difficult choices between high-paying surrogate contracts and long-term reputational risk.
Financial advisors noted that premium lifestyle, technology, and electric vehicle brands are increasingly replacing traditional tobacco and pan masala accounts for top-tier actors.
Market researchers project that the surrogate advertising segment could contract by up to 25% over the next two fiscal years as regulatory pressure mounts nationwide.
Legal teams representing Shah Rukh Khan, Ajay Devgn, and Tiger Shroff are currently preparing formal submissions to address the FDA's pending queries.
Industry observers expect the actors' legal counsels to emphasize their compliance with existing broadcasting codes while negotiating boundaries with state officials.
Mundhe made it clear that the FDA will evaluate the responses strictly on their legal merits without granting special exemptions.
"The law applies equally to everyone, regardless of their star power or cultural status," regulatory officials confirmed.
As the deadline for responses approaches, the entire Indian entertainment and advertising sector watches closely to see how the legal battle reshapes celebrity culture in Mumbai.